April 21, 2014. Members of the Patient, Consumer, and Public Health Coalition applaud FDA’s efforts to clearly and effectively communicate risks and benefits to consumers in direct-to-consumer (DTC) advertisements.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Statement of Dr. Diana Zuckerman Regarding FDA’s Announcement About Power Morcellation Devices for Uterine Fibroids and Other Uterine Surgery
April 17, 2014. We thank FDA for discouraging surgeons from using an FDA-approved device for women with uterine fibroids.
Read More »Coalition Letter to FDA Center for Drug Evaluation and Research About Flibanserin or “Pink Viagra”
April 8, 2014. As members of the Patient, Consumer, and Public Health Coalition, we are writing to support the agency’s evidence-based evaluation and decision regarding flibanserin.
Read More »NCHR Comment on the Importance of Including Women, Minorities, and the Elderly in Studies for New Drugs and Devices (FDASIA Section 907 Hearing)
April 1, 2014. The responsibility of collecting sufficiently representative demographic subgroup data sits solely on the shoulders of device and drug companies. The companies know how to persuade – they do it everyday in commercials. Similarly, if they identify persuasive incentives for patients to participate in studies, and minimize disincentives, patients will participate and be available for follow-up.
Read More »NCHR Comment to FDA Advisory Committee on Anti-Infective Drug Sivextro
March 31, 2014. We have concerns about Sivextro for the treatment of adult patients with acute bacterial skin and skin structure infections. The main goal in antibiotic drug development is finding new drugs to target strains that are resistant to currently available drugs.
Read More »